Madrigal Pharmaceuticals price target raised to $320 from $300 at Oppenheimer

Oppenheimer raised the firm’s price target on Madrigal Pharmaceuticals to $320 from $300 and keeps an Outperform rating on the shares following the Q4 results. The firm is encouraged by several potentially transformative events, including the priority review setting up resmetirom as potentially the first FDA-approved nonalcoholic steatohepatitis therapy, the analyst tells investors in a research note.